Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, Malaysia.
Expert Opin Ther Pat. 2020 May;30(5):375-387. doi: 10.1080/13543776.2020.1741547. Epub 2020 Mar 21.
: Pulmonary route is one of the preferred routes for the administration of therapeutically active agents for systemic as well as localized delivery. Chronic obstructive pulmonary disease (COPD), bronchial asthma, pneumonia, pulmonary hypertension, bronchiolitis, lung cancer, and tuberculosis are the major chronic diseases associated with the pulmonary system. Knowledge about the affecting factors, namely, the etiology, pathophysiology, and the various barriers (mechanical, chemical, immunological, and behavioral) in pulmonary drug delivery is essential to develop an effective drug delivery system. Formulation strategies and mechanisms of particle deposition in the lungs also play an important role in designing a suitable delivery system.: In the present paper, various drug delivery strategies, viz. nanoparticles, microparticles, liposomes, powders, and microemulsions have been discussed systematically, from a patent perspective.: Patent publications on formulation strategies have been instrumental in the evolution of new techniques and technologies for safe and effective treatment of pulmonary diseases. New delivery systems are required to be simple/reproducible/scalable/cost-effective scale for manufacturing ability and should be safe/effective/stable/controllable for meeting quality and regulatory compliance.
肺部给药途径是将治疗活性药物全身或局部递送至肺部的首选途径之一。慢性阻塞性肺疾病（COPD）、支气管哮喘、肺炎、肺动脉高压、细支气管炎、肺癌和肺结核是与肺部系统相关的主要慢性疾病。了解影响肺部药物输送的因素（即病因、病理生理学以及各种屏障（机械、化学、免疫和行为））对于开发有效的药物输送系统至关重要。制剂策略和颗粒在肺部的沉积机制在设计合适的输送系统方面也起着重要作用。
在本文中，从专利的角度出发，系统地讨论了各种药物输送策略，例如纳米颗粒、微粒、脂质体、粉末和微乳液。
制剂策略的专利出版物在推动安全有效的肺部疾病治疗新技术和技术的发展方面发挥了重要作用。新的输送系统需要具有简单/可重现/可扩展/具有成本效益的制造能力，并且需要安全/有效/稳定/可控，以满足质量和监管合规性的要求。
